OPINION
Rohm and Haas Company (“R & H”) brought this action against Brotech Corporation (“Brotech”) alleging that Brotech has willfully infringed four patents owned by R & H. While this Court has yet to confront the underlying patent issues involved in this case, since the time this suit was filed in March, 1990, every issue raised has been violently contested, and every step of this litigation has been marked by fierce controversy. Presently before us is the latest of the parties’ battles over what will be litigated in this case, and when and where the litigation will occur. More specifically, we now decide on the merits R & H’s motion for an injunction and Brotech’s cross motion to dissolve the injunction.
I. PROCEDURAL HISTORY
The present action was filed in March, 1990, alleging that Brotech had willfully infringed four of R & H’s patents for macroporous or macroreticular ion exchange resins, namely U.S. Patents 4,224,415 (’415), 4,382,124 (’124), 4,256,840 (’840), and 4,818,773 (’773). The first three of these four patents were all issued to Erich Meitzner and James Oline, and stem from the same parent application. These patents are referred to as the Meitzner-Oline or M/O patents.
In April, 1991, over one year after the present action was initiated, Brotech, along with Purolite International, Ltd. (“Purolite”), filed suit in the U.S. District Court for the Eastern District of Pennsylvania, Purolite International, Ltd., et al. v. Rohm and Haas Co., et al., Civil Action No. 91-CV-2740 (the “Pennsylvania action”), against R & H and six of its past and present subsidiaries and employees. The complaint in the Pennsylvania action alleges one antitrust count under the Sherman Act, 15 U.S.C. § 2, four counts asserting violations of RICO, 18 U.S.C. § 1962, and one count of common law fraud. All six counts arise out of an alleged pattern of fraud on the Patent and Trademark Office (“PTO”) practiced by defendants in the prosecution and enforcement of ten patents. Four of these patents are the patents-in-suit in the present action.
More specifically, the defendants in the Pennsylvania action are R & H, Duolite International, S.A. (“Duolite”), and five individuals. Duolite is a now defunct French corporation which once was a subsidiary of R & H. The five individuals are all past or present employees of R & H or its subsidiaries. The majority of the factual allegations in the Pennsylvania complaint assert that these defendants obtained ten patents, including the four patents-in-suit in this action, by various methods of fraud on the PTO. The additional patents named in the Pennsylvania complaint are four other Meitzner/Oline patents which stem from the same parent application as the three M/O patents at issue here, a patent that was declared invalid in 1983, and U.S. Patent 4,002,564 (’564), which is alleged to be related to the ’773 patent-in-suit here. The complaint also alleges acts of unfair competition concerning sales of factories for the manufacture of ion exchange resins.
After the Pennsylvania action had been instituted, R & H filed a motion for an injunction in this action, requesting that this Court order Brotech to dismiss the Pennsylvania action because the claims asserted by Brotech should have been raised as compulsory counterclaims in this action. R & H also argued that although Purolite is not a party to this action, it is a captive affiliate of Brotech, and that the requested *930 injunction should cover Purolite. On June 5, 1991, we held a teleconference with the parties during which we heard argument for and against R & H’s motion.
Following the argument, we found that R & H had made a sufficient preliminary-showing on the compulsory counterclaim issue, and by Order of June 5, 1991, we entered a preliminary injunction enjoining the parties from participating in the Pennsylvania action until after R & H’s motion for an injunction had been fully briefed, argued, and decided. Because Purolite has never been joined as a party to this action and we lacked sufficient information on the relationship between Brotech and Purolite, our preliminary injunction order did not name Purolite. The injunction did, however, extend to all those acting in concert with the parties, as well as the parties’ attorneys, agents, servants, employees, and subsidiaries.
Our Order of June 5, 1991 also set forth a schedule for briefing on the motion for an injunction. On June 19, 1991, however, Brotech, together with Purolite by special appearance, filed a separate motion to dissolve the injunction, and requested an emergency hearing to prevent the loss of critical evidence. The stated grounds for emergency was the impending departure from this country of a key witness. On June 21, 1991, this Court held another teleconference regarding Brotech and Purolite’s motion. By Order of June 21, 1991, we modified our injunction to permit the parties to take the deposition of the witness and thus grant the emergency relief sought. Having addressed the emergency nature of the motion, we then ordered that Brotech and Purolite’s motion be treated as a cross motion governed by the previously established briefing schedule.
Brotech and Purolite filed a notice of appeal of our June 5th and June 21st orders. As set forth in detail in our Orders of July 1, 1991 and July 11, 1991, we nonetheless concluded that we still possess jurisdiction to consider on the merits both R & H’s motion for an injunction and Brotech and Purolite’s cross motion, because the appeal of an order granting a preliminary injunction does not deprive the district court of jurisdiction to decide whether to grant permanent injunctive relief.
See, e.g., New York State Nat’l Org. for Women v. Terry,
We heard oral argument on these motions on July 19, 1991. By order of that date, we held that based on the information presented to us, we cannot at this time enter an injunction specifically naming Purolite. First, the evidence presented to us thus far on the structure of the corporate relationship between Brotech and Purolite is insufficient to prove that Purolite is covered by the terms of our preliminary injunction; second, this Court cannot currently exercise personal jurisdiction over Purolite; and third, this Court has not yet issued any order of finality on the merits of this action to be protected by an injunction against Purolite under the All Writs Act, 28 U.S.C. § 1651.
See In re Baldwin-United Corp.,
In addition, we reserved decision on the question of whether a permanent injunction should issue against Brotech, in order to give R & H an opportunity to respond to a late supplemental filing by Brotech. Having received and reviewed R & H’s response, we now address the compulsory counterclaim question as it pertains to Bro-tech.
II. WHETHER BROTECH’S CLAIMS IN THE PENNSYLVANIA ACTION SHOULD HAVE BEEN ASSERTED AS COMPULSORY COUNTERCLAIMS IN THE PRESENT ACTION
Pursuant to Fed.R.Civ.P. 13(a), a claim is a compulsory counterclaim “if it arises out of the transaction or occurrence that is the subject matter of the opposing party’s claim and does not require for its
*931
adjudication the presence of third parties of whom the court cannot acquire jurisdiction.” To determine whether a claim qualifies as a compulsory counterclaim, we must assess whether it bears a “logical relationship” to the opposing party’s claims.
Great Lakes Rubber Corp. v. Herbert Cooper Co.,
where separate trials on each of [the parties’] respective claims would involve a substantial duplication of effort and time by the parties and the courts. Where multiple claims involve many of the same factual issues, or the same factual and legal issues, or where they are offshoots of the same basic controversy between the parties, fairness and considerations of convenience and of economy require that the counterclaim-ant be permitted to maintain his cause of action. Indeed the doctrine of res judicata compels the counterclaimant to assert his claim in the same suit for it would be barred if asserted separately, subsequently.
Id.
Under Rule 13(a), several courts have found that antitrust and fraud claims similar to those asserted by Brotech in the Pennsylvania action are “logically related” to infringement claims in patent cases. For example, the court in
USM Corp. v. SPS Technologies, Inc.,
Since the fraud allegations necessary to invalidate the ... patent are identical to the fraud allegations which provide the basis for the antitrust claim, there can be no doubt that these claims, although grounded in different legal theories, are essentially identical. Furthermore, the fraudulent procurement of a patent claim, whether asserted as a defense to an infringement suit or brought separately as an antitrust claim, is “logically related” to a claim for patent infringement. As such, that claim must be presented under Rule 13(a) or it is forever barred.
Id. at 170.
Similarly,
Lewis Mfg. Co. v. Chisholm-Ryder Co.,
Brotech urges us to reject these analyses and instead to follow the Supreme Court’s decision in
Mercoid Corp. v. Mid-Continent Inv. Co.,
Brotech contends that
Mercoid
stands for the proposition that an antitrust claim under Section 4 of the Clayton Act is only a permissive counterclaim in any suit for patent infringement, and consequently the failure to assert such a counterclaim in a patent case will not bar the claim in a subsequent action. Yet, although it still stands as valid law,
Mercoid
has been widely and severely criticized, and most courts have narrowed it to its facts.
See, e.g., United States v. Eastport Steamship Corp.,
The
Lewis
court distinguished
Mercoid
based on the fact that in the earlier action Mercoid was not a party but was only defending another company; consequently, the
Lewis
court reasoned, Mercoid could not have been expected to raise the claim in the earlier litigation.
In an attempt to demonstrate that
Mercoid
is still intact and a binding precedent, Brotech cites six cases which have cited and relied upon
Mercoid.
Three of these cases,
Fowler v. Sponge Prod. Corp.,
Although the final two cases cited by Brotech are decisions of this district, neither provides a basis for reading
Mercoid
any more broadly than did the
USM
court.
Brady v. C.F. Schwartz Motor Co.,
In
Rixon,
this Court relied on
Mercoid
in deciding to hear an accused infringer’s antitrust counterclaim despite the existence of a prior judgment in a patent case in the U.S. District Court for the District of Kansas.
Thus,
Rixon
fits under the narrow
Mercoid
rule that antitrust claims based on patent misuse may be raised in a subsequent action. More importantly, the misuse at issue in
Rixon
was that of perpetrating fraud on the court in the prior Kansas action. The
Rixon
court found by clear and convincing evidence that Milgo and its counsel had knowingly presented false testimony to the Kansas court to convince that court that its patent was valid.
Id.
at 175. This Court therefore permitted Rixon to litigate its antitrust claim in the Delaware action largely because the case involved “ ‘a deliberately planned and carefully executed scheme to defraud ... a Court ... through the presentation of a theory of patentability manufactured by a patent holder out of whole cloth.’ ”
Id.
at 184 (citing
Hazel-Atlas Glass Co. v. Hartford-Empire Co.,
Having considered the cases interpreting
Mercoid,
we find that the decisions such as
USM Corp. v. SPS Technologies, Inc.,
Brotech seeks to escape this conclusion by arguing that the “roots test" formulation of the compulsory/permissive counterclaim test in
A. H. Gruetzmacher & Co. v. Massey-Ferguson, Inc.,
Nor is our conclusion that the Pennsylvania claims are compulsory counterclaims undermined by the fact that the Pennsylvania action involves six additional R & H patents and several additional parties. As outlined above, four of the six additional patents are Meitzner-Oline patents stemming from the same parent application as the three M/O patents-in-suit. Moreover, the alleged fraud involves a “liquid expulsion technique” claimed in all seven patents, and the parent patent for the group is one of the patents-in-suit in this action. Similarly, the ’564 patent is alleged to be related to the ’773 patent-in-suit here, and the same pattern of fraud is alleged against both of these two patents. Finally, the sixth additional patent was declared invalid in 1983. It therefore simply constitutes evidence of Brotech’s allegations of fraud, and does not expand the claims in the Pennsylvania action. The same may be said of the allegations concerning sales of ion exchange resin manufacturing plants.
Similarly, the addition of extra parties in the Pennsylvania action does not affect the compulsory counterclaim issue, as demonstrated by the case of
AMP, Inc. v. Zacharias,
The AMP court found that “Rule 13(a) is not limited in its application to original parties,” Slip Op. at 3, and concluded that despite the addition of several individual defendants in the later filed Illinois case, the claims involved should have been raised as compulsory counterclaims in the Florida case. The court relied in part on Fed. R.Civ.P. 13(h) which addresses joinder of parties for counterclaims, finding it “contemplates the situation where additional parties are required for the granting of complete relief.” Slip. Op. at 3. As in AMP, all the additional defendants in the Pennsylvania action are related to the company that owns the patents. Thus, their joinder does not alter our conclusion that the Pennsylvania claims are compulsory counterclaims in the present action. Furthermore, it is also noteworthy that the AMP case found that RICO claims alleging fraudulent procurement of a patent were logically related to claims alleging patent infringement.
*935 Finally, we note that the Rule 13(a) compulsory counterclaim test promotes judicial economy by requiring litigants to consolidate all related claims in one forum. Bro-tech’s counsel contended at oral argument that the present action is a simple patent case whose sole issues pertain to chemical compositions, whereas the Pennsylvania action involves a broad, sweeping pattern of fraud and monopoly unrelated to the chemical issues involved here. (Transcript, D.I. 143 at 20). We do not accept this characterization; the litigation to date in the present suit has been anything but simple and focused. In fact, in a case involving litigation as contentious as that in this action, our concerns for judicial economy are heightened.
Thus, we conclude that under Rule 13(a), the antitrust, RICO, and common law fraud claims asserted by Brotech in the Pennsylvania action should have been brought as compulsory counterclaims in the present action.
III. WHETHER AN INJUNCTION SHOULD ISSUE AGAINST BRO-TECH
Under the first-in-time rule, when two actions involve the same parties and issues, the Court hearing the earlier filed action may enjoin proceedings in the second action. As this Court has previously stated, “[t]he Court’s authority to enjoin a party within its jurisdiction from prosecuting the same cause of action in another suit in another court is undisputed.”
Bamdad Mechanic Co. v. United Technologies Corp.,
Given our determination of the compulsory counterclaim issue, we will invoke our authority to enjoin Brotech from litigating the later filed Pennsylvania action. Pursuant to Fed.R.Civ.P. 65(d), the injunction will extend to all those acting in concert with Brotech, as well as to Brotech’s attorneys insofar as they are acting in their capacities as Brotech’s attorneys, and to its officers, agents, servants, and employees, insofar as they are acting in those capacities. However, given our earlier determination that we do not presently possess authority to enjoin Purolite, we will not name Purolite in the injunction. As a result, unless Purolite is later demonstrated to have violated the terms of the injunction by acting in concert with Brotech, or unless this case reaches final determination and Purolite is found to be in privity with Brotech under the doctrines of res judicata and collateral estoppel, the Pennsylvania action will presumably proceed with Purolite as sole plaintiff. Since R & H is still a defendant in the Pennsylvania action, the injunction will not cover R & H.
IV. CONCLUSION
Brotech’s claims in the Pennsylvania action should have been brought in the present action as compulsory counterclaims under Fed.R.Civ.P. 13(a). Consequently, we will issue a permanent injunction, ordering Brotech to dismiss its later filed Pennsylvania claims, and enjoining it from participating any further in the Pennsylvania action in any capacity other than that of a third party witness.
Notes
At the time these motions were briefed and argued. Judge Roth was a District Judge for the United States District Court for the District of Delaware. She presently serves on the United States Court of Appeals for the Third Circuit.
. We expressly decline to decide the issue of whether Brotech has properly asserted a counterclaim in this action alleging inequitable conduct by R & H. That question may be resolved in connection with the pending cross motions for summary judgment.
. Brotech’s counsel contended at oral argument that the specific type of fraudulent procurement alleged in the Pennsylvania action is unrelated to chemistry and patent law. Brotech has charged that the inventors of the R & H patents filed an affidavit with the PTO falsely stating that they had tested all the examples presented and none worked. Brotech’s counsel argued that the falsity of the affidavit was not due to chemistry, but to the fact that the inventors had actually tested only one of the three examples, and that had they tested the other two examples, the inventors would have discovered that they did successfully produce a macroporous resin. (Transcript, Docket Item 143 at 51). This argument does not establish that the Pennsylvania claims are free from issues of chemistry. Although the failure to perform tests may be proven without resort to chemical analysis, the allegation that the other two examples did work does involve chemistry.
In any event, even were the chemical compositions of the patented and alleged infringing products completely irrelevant to the Pennsylvania claims, allegations of fraudulent procurement of a patent still involve fundamental issues of patent law which are logically related to infringement issues. For example, to determine whether an applicant had practiced fraud on the PTO, the factfinder must assess what evidence must be presented to the PTO to obtain legitimate approval of a given patent application.
